Nevertheless, it is unknown whether mIL‐6R blockade‐mediated NF‐κB inhibition reduces excessive release of Ccl2 thereby alleviating inflammatory responses in SIRS. This evidence concerns the gene CCL2 and systemic inflammatory response syndrome.